Viewing Study NCT02537366


Ignite Creation Date: 2025-12-24 @ 4:18 PM
Ignite Modification Date: 2025-12-28 @ 5:15 PM
Study NCT ID: NCT02537366
Status: COMPLETED
Last Update Posted: 2017-03-09
First Post: 2015-08-21
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Dexmedetomidine for Non-invasive Ventilation After Chest Trauma
Sponsor: University Hospital, Grenoble
Organization:

Study Overview

Official Title: Dexmedetomidine for Non-invasive Ventilation After Chest Trauma (VENDETTA)
Status: COMPLETED
Status Verified Date: 2017-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: VENDETTA
Brief Summary: Crossover randomized controlled double blinded trial :

* The primary endpoint is the duration of Non Invasive Ventilation (NIV) session (minutes) with dexmedetomidine (DEX) or placebo.
* Secondary endpoints will be the sedation level as assessed by the Richmond Agitation Sedation Scale (RASS), the number of interventions to allow the completion of NIV session, the pain intensity level as assessed by visual analogue scale, the morphine and ketamine consumption during NIV sessions, the comparison of blood gas measurements before and after NIV sessions, the reproducibility of NIV cycles. The side effects of DEX will be notified.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: